-DOCSTART- -X- O
There -X- _ O
is -X- _ O
a -X- _ O
pressing -X- _ O
need -X- _ O
to -X- _ O
develop -X- _ O
new -X- _ O
antiviral -X- _ O
treatments -X- _ O
; -X- _ O
of -X- _ O
the -X- _ O
60 -X- _ O
drugs -X- _ O
currently -X- _ O
available -X- _ O
, -X- _ O
half -X- _ O
are -X- _ O
aimed -X- _ O
at -X- _ O
HIV-1 -X- _ O
and -X- _ O
the -X- _ O
remainder -X- _ O
target -X- _ O
only -X- _ O
a -X- _ O
further -X- _ O
six -X- _ O
viruses. -X- _ O
This -X- _ O
demand -X- _ O
has -X- _ O
led -X- _ O
to -X- _ O
the -X- _ O
emergence -X- _ O
of -X- _ O
possible -X- _ O
peptide -X- _ O
therapies -X- _ O
, -X- _ O
with -X- _ O
15 -X- _ O
currently -X- _ O
in -X- _ O
clinical -X- _ O
trials. -X- _ O
Advancements -X- _ O
in -X- _ O
understanding -X- _ O
the -X- _ O
antiviral -X- _ O
potential -X- _ O
of -X- _ O
naturally -X- _ O
occurring -X- _ O
host -X- _ O
defence -X- _ O
peptides -X- _ O
highlights -X- _ O
the -X- _ O
potential -X- _ O
of -X- _ O
a -X- _ O
whole -X- _ O
new -X- _ O
class -X- _ O
of -X- _ O
molecules -X- _ O
to -X- _ O
be -X- _ O
considered -X- _ O
as -X- _ O
antiviral -X- _ O
therapeutics. -X- _ O
Cationic -X- _ B-Intervention
host -X- _ I-Intervention
defence -X- _ I-Intervention
peptides -X- _ I-Intervention
, -X- _ I-Intervention
such -X- _ I-Intervention
as -X- _ I-Intervention
defensins -X- _ I-Intervention
and -X- _ I-Intervention
cathelicidins -X- _ I-Intervention
, -X- _ O
are -X- _ O
important -X- _ O
components -X- _ O
of -X- _ O
innate -X- _ O
immunity -X- _ O
with -X- _ O
antimicrobial -X- _ O
and -X- _ O
immunomodulatory -X- _ O
capabilities. -X- _ O
In -X- _ O
recent -X- _ O
years -X- _ O
they -X- _ O
have -X- _ O
also -X- _ O
been -X- _ O
shown -X- _ O
to -X- _ O
be -X- _ O
natural -X- _ B-Outcome
, -X- _ I-Outcome
broad-spectrum -X- _ I-Outcome
antivirals -X- _ I-Outcome
against -X- _ I-Outcome
both -X- _ I-Outcome
enveloped -X- _ I-Outcome
and -X- _ I-Outcome
non-enveloped -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
, -X- _ I-Outcome
influenza -X- _ I-Outcome
virus -X- _ I-Outcome
, -X- _ I-Outcome
respiratory -X- _ I-Outcome
syncytial -X- _ I-Outcome
virus -X- _ I-Outcome
and -X- _ I-Outcome
herpes -X- _ I-Outcome
simplex -X- _ I-Outcome
virus. -X- _ I-Outcome
Here -X- _ O
we -X- _ O
review -X- _ O
the -X- _ O
antiviral -X- _ O
properties -X- _ O
of -X- _ O
several -X- _ O
families -X- _ O
of -X- _ O
these -X- _ O
host -X- _ B-Intervention
peptides -X- _ I-Intervention
and -X- _ O
their -X- _ O
potential -X- _ O
to -X- _ O
inform -X- _ O
the -X- _ O
design -X- _ O
of -X- _ O
novel -X- _ O
therapeutics -X- _ O
. -X- _ O

